|Bid||9.70 x 900|
|Ask||10.25 x 1000|
|Day's Range||9.78 - 10.18|
|52 Week Range||1.42 - 10.38|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
The Pasadena, California-based company said it had a loss of 18 cents per share. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
The Pasadena, California-based company said it had a loss of 18 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.
Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.
Categories: Yahoo FinanceGet free summary analysis Arrowhead Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Arrowhead Pharmaceuticals, Inc. – Alnylam Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Shire PLC Sponsored ADR, Ligand Pharmaceuticals Incorporated, Inovio Pharmaceuticals, Inc. and Abeona Therapeutics, Inc. (ALNY-US, ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Arrowhead Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ARWR-US. Comparing the performance and risk of Arrowhead Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Defensive telecoms gained 2.6% on a positive day for U.S. equities, while treasury bonds were unchanged. The S&P 500 Index gained 0.2%, the Dow Jones Industrial Average surged 0.5% and the Nasdaq Composite fell 0.2%.
On December 6, Arrowhead (ARWR) presented new data of ARC-520 from its Phase II clinical study in patients with chronic hepatitis B virus (HBV) infection at the 22nd biennial HEP DART meeting held in Kona, Hawaii, from Dec. 3-7. The new data demonstrated that 2 of 3 (66.7%) HBeAg positive patients and 2 of 5 (40%) HBeAg negative patients treated with ARC-520 had a sustained host response that persisted after therapy was removed. In the 4 patients that had a sustained host response, the company observed reductions in HBsAg of 5.0, 3.1, 2.4, and 0.6 log10 from baseline, respectively.
Arrowhead Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm presented new data from its midstage study for the treatment of hepatitis B infection.